Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
BeOne Medicines
Eli Lilly and Company
MOMA Therapeutics
Eli Lilly and Company
Eli Lilly and Company
Nammi Therapeutics Inc
Beijing Biotech
Exscientia AI Limited
Conjupro Biotherapeutics, Inc.
Conjupro Biotherapeutics, Inc.
Zumutor Biologics Inc.
858 Therapeutics, Inc.
Orano Med LLC
Filamon LTD
Atavistik Bio, Inc
PMV Pharmaceuticals, Inc
AstraZeneca
Alterome Therapeutics, Inc.
Monte Rosa Therapeutics, Inc
Psyence Australia Pty Ltd
ViroMissile, Inc.
Novartis
AstraZeneca
Tizona Therapeutics, Inc
MBrace Therapeutics
Clasp Therapeutics, Inc.
Angiex, Inc.
Sapience Therapeutics
IDEAYA Biosciences
Daiichi Sankyo
Guerbet
Oscotec Inc.
Adela, Inc
Natera, Inc.
Second Life Therapeutics
Apollo Therapeutics Ltd
Innate Pharma
Acerand Therapeutics Limited
Complement Theory Inc.
Tanabe Pharma America, Inc.
XEOS Medical
NeoTX Therapeutics Ltd.
NantCell, Inc.
Nuvation Bio Inc.
Massive Bio, Inc.
Incyte Corporation
AVM Biotechnology Inc
Pfizer
Exelixis